7 results
To compare the therapeutic benefit of maintenance pazopanib versus placebo after first line treatment of NSCLC.
Primary Objectives:- To evaluate whether early metabolic response is correlated to clinical benefit (defined as PFS).- To evaluate the effect of age (>= 70 years) on pazopanib pharmacokinetics (AUC0-24hr).Secondary Objectives:- To evaluate…
The primary goal of this research is to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for sunitinib and pazopanib in patients with metastatic renal cell carcinoma, so that the possible use of biomarkers can be tested as predictors for the…
The main objective of this pilot study is to determine intratumoral concentrations of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
primary• To determine the safety and feasibility of PK guided dosing of pazopanib secondary• Evaluation of the dried blood spot procedure• To determine the objective response rate (according RECIST 1.1)• To determine the time to tumor progression…
To determine the plasma pharmacokinetics of Pazopanib after intake of different doses of PazSol001.To determine the preliminary safety and tolerability profile of PazSol001.
To evaluate the efficacy of PTC857 in reducing disease progression in subjects with amyotrophic lateral sclerosis (ALS)